Expression of osteoprotegerin and osteoprotegerin ligand in giant cell tumor of bone and its clinical significance

Yu,Xiuchun; Kong,Weiqing; Zheng,Kai

doi:10.3892/ol.2013.1199

Expression of osteoprotegerin and osteoprotegerin ligand in giant cell tumor of bone and its clinical significance

Authors:
- Xiuchun Yu
- Weiqing Kong
- Kai Zheng
View Affiliations

Affiliations: Orthopedic Department, The General Hospital of Jinan Military Commanding Region, Jinan, Shandong 250031, P.R. China
Published online on: February 19, 2013 https://doi.org/10.3892/ol.2013.1199
Pages: 1133-1139

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In this study, we used a substance P (SP) immunohistochemical method to analyze the expression localization of osteoprotegerin (OPG) and osteoprotegerin ligand (OPGL) in giant cell tumor (GCT) of the bone, and to detect the clinical significance of their expression. The data showed that the positive expression rate of OPG in the multinucleated giant cells (MGCs) and stromal cells (STCs) of GCT was 80.65 and 74.19%, respectively. The positive expression rate of OPG in MGCs was correlated with age and prognosis (P<0.05), but not in STCs. The strength of positive OPG expression in MGCs and STCs was negatively correlated with prognosis (rs=‑0.397, P<0.05; rs=‑0.390, P<0.05, respectively). The positive expression rate of OPGL in the MGCs and STCs was 41.94 and 67.74%, respectively. The positive expression rate of OPGL in the MGCs was correlated with age and prognosis (P<0.05); the strength of OPGL expression in MGCs was positively correlated with Campanicci's grade and recurrence. Additionally, the positive expression rate of OPGL in STCs was correlated with age and Jaffe's grade (P<0.05). The strength of OPGL expression in STCs was negatively correlated with Jaffe's grade (rs=‑0.534, P<0.05). In conclusion, OPG and OPGL are expressed in MGCs and STCs in GCT of the bone. The invasion of tumor cells was positively correlated with OPGL in MGCs, which confirmed that MGCs participate in the process of osteolytic destruction of GCT of bone.

View Figures

View References

1	Wülling M, Delling G and Kaiser E: The origin of the neoplastic stromal cell in giant cell tumor of bone. Hum Pathol. 34:983–993. 2003.PubMed/NCBI
2	Turcotte RE, Wunder JS, Isler MH, Bell RS, Schachar N, Masri BA, Moreau G and Davis AM: Giant cell tumor of long bone: a Canadian Sarcoma Group study. Clin Orthop Relat Res. 397:248–258. 2002. View Article : Google Scholar : PubMed/NCBI
3	Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Goto M, Mochizuki SI, Tsuda E, Morinaga T, Udagawa N, et al: A novel molecular mechanism modulating osteoclast differentiation and function. Bone. 25:109–113. 1999. View Article : Google Scholar : PubMed/NCBI
4	Takahashi N, Udagawa N and Suda T: A new member of tumor necrosis factor ligand family, ODFI/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function. Biochem Biophys Res Comm. 256:449–455. 1999. View Article : Google Scholar : PubMed/NCBI
5	Xu LZ and Yang WT: The criteria of immunohistochemistry reaction results. China Oncology. 6:229–231. 1996.
6	Guo J, Wang Y, Ni J, Yang ZY, Huang JX and Bai JZ: Expression and role of osteoclast differentiation associated cytokine in giant cell tumors. Chinese J of CRTER. 11:242–246. 2007.
7	Meng XM, Yu SF and Wei MJ: Expression of receptor activator of NF-kappa B ligand and osteoprotegerin protein in the giant cell lesions of jaw. Chinese J of Stomatology. 40:294–297. 2005.(In Chinese).
8	Hu Y and Yu S: Gene expression of osteoprotegerin and osteoclast differentiation factor in giant cell tumor. Chinese J of Pathology. 31:128–131. 2002.PubMed/NCBI
9	Liu B, Yu SF and Li TJ: Multinucleated giant cells in various forms of giant cell containing lesions of the jaws express features of osteoclasts. J Oral Pathol Med. 32:367–375. 2003. View Article : Google Scholar : PubMed/NCBI
10	Atkins GJ, Haynes DR, Graves SE, Evdokiou A, Hay S, Bouralexis S and Findlay DM: Expression of osteoclast differentiation signals by stromal elements of giant cell tumor. J Bone Miner Res. 15:640–649. 2000. View Article : Google Scholar : PubMed/NCBI
11	Huang L, Xu J, Wood DJ and Zheng MH: Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation. Am J Pathol. 156:761–767. 2000. View Article : Google Scholar : PubMed/NCBI
12	Roux S, Amazit L, Meduri G, Guiochon-Mantel A, Milgrom E and Mariette X: RANK (receptor activator of nuclear factor kappa B) and RANK ligand are expressed in giant cell tumors of bone. Am J Clin Pathol. 117:210–216. 2002. View Article : Google Scholar : PubMed/NCBI
13	Zhu Y, Dong SK and Fan QH: Expression of osteoclast differentiation factor and its receptor and decoy receptor in giant cell tumor of bone. J Southeast Univ (Medical Science Edition). 24:330–333. 2005.
14	Thompson SH, Bischoff P and Bender S: Central giant cell granuloma of the mandible. J Oral Maxillofac Surg. 41:743–746. 1983. View Article : Google Scholar : PubMed/NCBI
15	Liu B, Yu SF and Pang SZ: Purification and study of the characteristics of the multinucleated giant cells of the giant cell tumor. Journal of Peking University (Health Sciences). 35:23–27. 2003.(In Chinese).
16	Atkins GJ, Kostakis P, Vincent C, Farrugia AN, Houchins JP, Findlay DM, Evdokiou A and Zannettino AC: RANK expression as a cell surface marker of human osteoclast precursors in peripheral blood, bone marrow, and giant cell tumors of bone. J Bone Miner Res. 21:1339–1349. 2006. View Article : Google Scholar : PubMed/NCBI